Clinical trials: in Peru
Rheumatoid Arthritis
Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis (Taski-3)
The purpose of this study is to determine whether the Spleen Tyrosine Kinase (Syk) Inhibitor, R935788 (R788) at a dose of 100 mg, tablet, orally, twice-a-day is effective in the treatment of Rheumatoid Arthritis in patients who…
- Trial name
- Taski-3 (NCT00665626)
- Testing
- Fostamatinib disodium (R935788)
- Where
- 44 sites in United States, Belgium and 5 more
- Volunteers
- 219 people
- Sponsor
- Rigel Pharmaceuticals
Systemic Lupus Erythematosus
An Adaptive Phase II Study to Evaluate the Efficacy, Pharmacodynamics, Safety and Tolerability of GSK2586184
This is an adaptive, dose ranging, Phase II study to investigate the relationship between repeat doses of GSK2586184 and the pharmacodynamic effect and clinical efficacy in patients with active systemic lupus erythematosus (SLE).
- Trial name
- NCT01777256
- Testing
- GSK2586184 50 mg, GSK2586184 100 mg, GSK2586184 200 mg
- Where
- 53 sites in Argentina, Chile and 14 more
- Volunteers
- 51 people
- Sponsor
- GlaxoSmithKline
Pain
Diclofenac 25mg/Paracetamol 500 mg and Diclofenac 50 mg/Paracetamol 500 mg for Patients With Pain
The purpose of this study is to collect adverse events and identify risk factors in patients that are taking Dolocordralan Extra 25® and Dolocordralan Extra Forte®
- Trial name
- NCT02651363
- Where
- Peru
- Volunteers
- 374 people
- Sponsor
- Bristol-Myers Squibb
Diabetes Mellitus, Type 2
Thiazolidinedione Intervention With Vitamin D Evaluation
This study will answer two separate questions. The first question is to test the cardiovascular effects of long-term treatment with rosiglitazone or pioglitazone when used as part of standard of care compared to similar standard…
- Trial name
- TIDE (NCT00879970)
- Testing
- pioglitazone, rosiglitazone, Vitamin D
- Where
- 331 sites in United States, Argentina and 23 more
- Volunteers
- 1,332 people
- Sponsor
- GlaxoSmithKline
Type 2 Diabetes
Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients
Primary objective: To evaluate the effect of lixisenatide versus placebo over a period of 24 weeks on glycemic control, as evaluated by glycosylated hemoglobin (HbA1c) reduction, in older type 2 diabetes participants (T2DM) who…
- Trial name
- GetGoal-O (NCT01798706)
- Testing
- Lixisenatide (AVE0010), Antidiabetic background therapy
- Where
- 83 sites in United States, Australia and 11 more
- Volunteers
- 350 people
- Sponsor
- Sanofi
Purpura, Thrombocytopaenic, Idiopathic
RAISE: Randomized Placebo-Controlled Idiopathic Thrombocytopenic Purpura (ITP) Study With Eltrombopag
The rationale for this Phase III study is to evaluate the 6 month safety and efficacy of eltrombopag in the treatment of previously treated subjects with chronic ITP.
- Trial name
- RAISE (NCT00370331)
- Testing
- eltrombopag
- Where
- 115 sites in United States, Austria and 23 more
- Volunteers
- 197 people
- Sponsor
- GlaxoSmithKline
Prostate Cancer
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Primary Objective: To demonstrate the non inferiority in term of overall survival (OS) of Cabazitaxel 20 mg/m² (Arm A) versus Cabazitaxel 25 mg/m² (Arm B) in combination with prednisone in participants with metastatic castration…
- Trial name
- PROSELICA (NCT01308580)
- Testing
- Cabazitaxel (XRP6258), Prednisone (or Prednisolone)
- Where
- 172 sites in United States, Argentina and 20 more
- Volunteers
- 1,200 people
- Sponsor
- Sanofi
Purpura, Thrombocytopaenic, Idiopathic
EXTEND (Eltrombopag Extended Dosing Study)
An open-label, dose-adjustment, extension study to evaluate the safety and efficacy of eltrombopag for the treatment of subjects with idiopathic thrombocytopenic purpura (ITP) who have previously been enrolled in an eltrombopag…
- Trial name
- EXTEND (NCT00351468)
- Testing
- eltrombopag olamine (SB-497115-GR)
- Where
- 110 sites in United States, Australia and 29 more
- Volunteers
- 302 people
- Sponsor
- Novartis Pharmaceuticals
COPD, COPD Exacerbation
Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of Long-acting β2-agonist (LABA) and Inhaled Corticosteroid (ICS)
To demonstrate the additional benefit of roflumilast when added on to fixed-dose combination (FDC) LABA/ICS in the reduction of exacerbations in subjects with severe to very severe COPD.
- Conditions
- COPD, COPD Exacerbation, Lung Diseases, Respiratory Disorders
- Trial name
- NCT01443845
- Testing
- Roflumilast
- Where
- 338 sites in United States, Argentina and 15 more
- Volunteers
- 2,354 people
- Sponsor
- AstraZeneca
Breast Cancer
An Observational Study on Human Epidermal Growth Factor Receptor (HER) 2 Status of Breast Invasive Carcinoma in Latin American Participants
This is a descriptive, prospective, observational and epidemiological study on participants recently diagnosed with breast cancer to evaluate the HER2 status by IHC and SISH procedures.
- Trial name
- NCT02535026
- Where
- 4 sites in Peru, Uruguay
- Volunteers
- 580 people
- Sponsor
- Hoffmann-La Roche
Epilepsy, Tonic-Clonic
Treatment Of Primary Generalized Tonic-Clonic Seizures With An Investigational New Drug
The purpose of this study is to evaluate the effectiveness and safety of an investigational new drug for supplemental therapy in subjects with primary generalized tonic-clonic (PGTC) seizures.
- Trial name
- NCT00043901
- Testing
- lamotrigine
- Where
- 87 sites in United States, Argentina and 2 more
- Volunteers
- 141 people
- Sponsor
- GlaxoSmithKline
Carcinoma, Non-Small-Cell Lung
LUX-Lung 5: Afatinib Plus Weekly Paclitaxel Versus Investigator's Choice of Single Agent Chemotherapy Following Afatinib Monotherapy in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib
The primary objective of this randomized, open-label, active-controlled, multi-center trial is to determine the efficacy of BIBW 2992 given as an add-on to chemotherapy in patients with NSCLC Stage IIIb or IV progressing after…
- Trial name
- NCT01085136
- Testing
- Investigator´s choice of chemotherapy, BIBW 2992
- Where
- 97 sites in Argentina, Australia and 21 more
- Volunteers
- 1,154 people
- Sponsor
- Boehringer Ingelheim
Systemic Juvenile Idiopathic Arthritis
Single-dose Study to Assess Efficacy of Canakinumab (ACZ885) in Patients With Active Juvenile Idiopathic Arthritis (SJIA)
This study assessed the initial efficacy and safety of canakinumab over a 4 week period in patients with systemic juvenile idiopathic arthritis (SJIA) having a flare.
- Trial name
- β-SPECIFIC 1 (NCT00886769)
- Testing
- Canakinumab
- Where
- 91 sites in United States, Argentina and 20 more
- Volunteers
- 84 people
- Sponsor
- Novartis Pharmaceuticals
Bipolar Disorder
Open Label Extension Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar I Disorder
This extension study is designed to assess the long-tem tolerability and safety of licarbazepine in patients who completed the 6-week double-blind study CLIC477D2303.
- Trial name
- NCT00139594
- Testing
- licarbazepine
- Where
- 44 sites in United States, Austria and 11 more
- Volunteers
- 181 people
- Sponsor
- Novartis
Schizophrenia
SB-773812 Administered In Adults With Schizophrenia
This is a two part study designed to evaluate the safety and efficacy of SB-773812 in the treatment of acute schizophrenia. Subjects with acute schizophrenia will be randomized in an adaptive design study to receive placebo…
- Trial name
- NCT00259870
- Testing
- SB-773812, Olanzapine
- Where
- 45 sites in United States, Belgium and 5 more
- Volunteers
- 338 people
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus, Type 2
Study In People With Type 2 Diabetes
This Phase 2 dose-ranging study will evaluate the efficacy, safety and tolerability of a range of doses of GW677954 compared with placebo over sixteen weeks of treatment in subjects with T2DM (Type 2 Diabetes Mellitus).
- Trial name
- NCT00196989
- Testing
- Pioglitazone, GW677954
- Where
- 143 sites in United States, Argentina and 11 more
- Volunteers
- 448 people
- Sponsor
- GlaxoSmithKline
Thrombocytopaenia
SB-497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adult Cancer Patients Receiving Chemotherapy
SB497115 is an oral agent which activates the thrombopoietin receptor and increases platelet counts in healthy volunteers. This study is examining several different doses of SB497115 versus placebo as treatment for patients with…
- Trial name
- NCT00102726
- Testing
- SB497115
- Where
- 95 sites in United States, Argentina and 17 more
- Volunteers
- 183 people
- Sponsor
- GlaxoSmithKline
Purpura, Thrombocytopaenic, Idiopathic
LENS - Long-term Eltrombopag Observational Study
A long term observational ocular safety study in adults who have received study medication (either active drug or placebo) in a phase II or III clinical study evaluating eltrombopag.
- Trial name
- LENS (NCT00643929)
- Testing
- Eltrombopag
- Where
- 71 sites in United States, Australia and 19 more
- Volunteers
- 164 people
- Sponsor
- GlaxoSmithKline
Bipolar Disorder
Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar Disorder
The purpose of this study is to evaluate the effectiveness and tolerability of an investigational drug for the treatment of manic episodes of bipolar disorder.
- Trial name
- NCT00107926
- Testing
- Licarbazepine
- Where
- 44 sites in United States, Austria and 11 more
- Volunteers
- 343 people
- Sponsor
- Novartis Pharmaceuticals
Bacterial Pneumonia
Comparative Study of Ceftaroline vs. Ceftriaxone in Adults With Community-Acquired Pneumonia
The purpose of the study is to determine if the antibiotic ceftaroline is safe and effective in the treatment of community-acquired pneumonia in adults.
- Trial name
- CAP (NCT00509106)
- Testing
- Ceftaroline fosamil for Injection, Ceftriaxone
- Where
- 134 sites in United States, Argentina and 13 more
- Volunteers
- 622 people
- Sponsor
- Forest Laboratories